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ABSTRACT 
 
Management of castration resistant prostate cancer is limited by 
androgen receptor reactivation resulting in loss of remission. A recent 
study indicated that abiraterone exhibits antagonist activity towards the 
androgen receptor in addition to CYP17A1 inhibition.Metribolone has 
demonstrable in vitro and in vivo high affinity for the AR thus it was 
established as a benchmark against which the affinity of abiraterone 
and de novo designed non-steroidal molecules could be compared. 
Binding affinities of abiraterone manually superimposed onto the 
steroid scaffold of metribolone (pKd 7.16) and abiraterone that was 
allowed limited rotation (pKd 7.23)were comparable to metribolone 
(pKd 7.44).The de novo study generated an 8 analogue molecular 
series with affinities ranging between 5.26 and 7.23. This study 
yielded sufficient analogues that may be proposed for further 
molecular optimisation to yield innovative non-steroidal high affinity 
molecules with superior side-effect profiles for the management of 
prostate cancer. 
 
Introduction: 
Advanced state prostate cancer initially responds 
well to medical or surgical castration only to result in a 
castration-resistant state. Castration resistant prostate cancer 
(CRPC) refers to the state of the disease whereby the 
prostate-specific antigen continues to increase which 
indicates androgen receptor (AR) reactivation resulting in 
loss of remission followed by the development of disease-
related symptoms.1 Older terminologies used to describe 
advanced state prostate cancer such as hormone-refractory 
and androgen-independent are no longer appropriate as 
evidence has shown that growth may still be dependent on 
AR signalling. Androgen signalling is mediated through the 
AR; the inactive form of the AR is initially bound to heat 
shock proteins but is activated on binding to androgens 
resulting in the dissociation of heat shock proteins in order to 
allow transcription pathways for androgen-dependent genes. 
However, AR mutation may occur in CRPC leading to 
potential loss in AR specificity to androgens thus resulting in 
an increased affinity towards oestrogens, progesterone and 
anti-androgens.2 
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Studies over the past decade have shown that 
CRPC may still remain dependent on AR signalling for 
growth and these insights have led to the development of new 
agents which specifically target the resistance causing 
alterations occurring in the signalling pathway of the AR in 
CRPC.1, 3Prostate cancer accounts for 11% of male cancer 
deaths4 thus drug design at the AR is still of significant 
importance owing to the fact that current therapy is not 
curative. 
CRPC treatment witnessed significant 
improvement with the April 2011 Food and Drug 
Administration (FDA) and the September 2011 European 
Medicine’s Agency (EMEA) approval of the CYP17A1 
inhibitor abiraterone acetate for use in combination with 
prednisone for the treatment of metastatic CRPC. Abiraterone 
acts by inhibiting the CYP17A1enzyme which plays a critical 
role in the androgen biosynthetic pathway specifically in the 
formation of dehydroepiandrosterone (DHEA) and 
androstenedione, the precursors of testosterone (Ref. Fig. 1).5, 
6It is important to note that recent studiesindicatedthat 
abiraterone exhibitsantagonist activity towards the AR in 
addition to CYP17A1 inhibition.In vitro data was indicative 
of the fact that abiraterone exhibits a dose proportional 
inhibition of both wild type and mutant AR variants with the 
most significant inhibitory effect being observed at doses 
≤10µmol L-1, suggesting a dual mode of action for this drug.7 
It was consequently concluded that abiraterone binds with 
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high affinity to CYP17A1 and with lower affinity to the   
AR.7, 8 
The CYP inhibitor abiraterone is a pregnenolone 
derivative (Ref. Fig. 2). Its key design features include the 3-
pyridyl substituent and 16, 17- double bond. The 3-pyridyl 
moiety appears to have the correct orientation for optimum 
binding to the haem iron of the CYP17A1. Evidence gathered 
from structure activity relationships (SARs) have concluded 
that the 3-pyridyl substituent results in more potent inhibition 
when compared to 2-pyridyl substituents, and even more so 
in comparison to 4-pyridyl substituents. It has also been 
postulated that the 16, 17- double bond is responsible for the 
irreversible inhibition of CYP17A1.9, 10, 11 
 
 
Figure 1: A Schematic Representation of Steroidogenesis. 
 
 
 
 
 
 
Figure 2: The 2D structures of Metribolone and Abiraterone 
Metribolone                             Abiraterone 
 
Through its CYP17A1 inhibitory effect, abiraterone inhibits 
the enzymes 17α-hydroxylase and C17,20 lyase; which play a 
critical role in the production of cortisol and androgen 
synthesis. 17α-hydroxylase converts progesterone into 17α-
hydroxyprogesterone and pregnenolone into 17α-
hydroxypregnenolone; while C17,20lyase converts 17α-
hydroxyprogesterone and 17α-hydroxypregnenolone into 
androstenedione and DHEA (Ref. Fig. 
1).Adrenocorticotropic hormone (ACTH) induces the  
 
conversion of cholesterol into pregnenolone, and is kept in 
check via negative feedback triggered by an increased 
cortisol level. By blocking the activity of 17α-hydroxylase, 
cortisol production is diminished and the negative feedback 
effect on ACTH is removed, leading to an accumulation of 
ACTH. Thus abiraterone must be given with a low dose of a 
glucocorticoid in order to avoid side effects that would 
otherwise result from an accumulation of ACTHincluding 
fluid retention, hypokalaemia, and hypertension.2, 7, 9 
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Through this study we report the use of abiraterone 
as a lead molecule in the de novo design of novel non-
steroidal AR antagonists suitable for the long term 
management of prostate cancer.  
 
Material and Methods: 
The pdb crystallographic deposition 1E3G was 
selected as a template for this study.121E3G describes the 
bound coordinates of the human AR, crystallised as a 
monomer and bound to the small agonist molecule 
metribolone. The 3D coordinates of this deposition were read 
into SYBYL13 ensuring preservation of the bound co-
ordinates of the complex and consequently its suitability to 
be utilised as a template for this study. Molecular 
simplification of the AR through the removal of co-
crystallised water molecules was based on the premise that 
literature indicates the absence of water molecules critical to 
ligand binding.12 This process was executed in SYBYL in 
order to reduce computer intensiveness in subsequent 
calculations. The metribolone molecule was subsequently 
extracted from its LBP and saved in mol2 format with the 
now apo AR being saved in pdb format (Ref. Fig. 3). These 
files were exported to Xscore14, which through its static 
algorithm quantified a predicted in silico affinity (pKd) of 
metribolone for its cognate AR_LBP. Given that metribolone 
has demonstrable in vitroand in vivo high affinity for the AR, 
this computed figure was established as a benchmark against 
which the affinity of abiraterone and of the de novo designed 
molecules could be compared.   
 
Figure 3 (A):  1E3G depicting the AR               
bound to the ligand metribolone 
 
Figure 3(B): AR void of ligand & water 
molecules 
 
 
Figure 3 (c): Depicts the extracted ligand 
metribolone using Pymol® 
 
 
 
De novoin silico design was carried out using 
LigBuilder v1.2.15 The extracted metribolone molecule was 
used to probe the AR_LBP such that a 3D image of the LBP 
and a proposed pharmacophoric structure (Ref. Fig.5) based 
on the bound coordinates of metribolone were generated.  
The abiraterone molecule was constructed and optimised in 
SYBYL. Two methodologies were considered for the 
estimation of the LBA of abiraterone for the AR_LBP. In the 
first approach an assumption that the steroidal scaffolds of 
metribolone and abiraterone could occupy identical positions 
within the AR_LBP was made. Consequently, the steroidal 
scaffold of abiraterone (Ref. Fig. 2) was manually 
superimposed onto that of metribolone. The new coordinates 
of abiraterone were saved in mol2 format and exported 
together with the apoAR into Xscore for in 
silicoquantification of predicted affinity for the AR in a 
process that was analogous to that carried out previously for 
metribolone.  
Based on the premise that ligand:protein complexes 
are essentially dynamic, a second approach was employed in 
order to attempt quantification of the LBA of abiraterone for 
the AR_LBP. This was carried out utilising the similarity 
suite embedded in SYBYL which essentially directs a test 
ligand (in this case abiraterone) into a target LBP (in this case 
the AR_LBP) based on the bound coordinates of a small 
molecule of established affinity for the target (in this case 
metribolone for the AR_LBP). The advantage of this method 
is that the introduced molecule (in this case abiraterone), is 
allowed conformational freedom within the target AR_LBP. 
This process resulted in the identification of the 21 
conformations with highest affinity for the AR_LBP, where 
affinity was subsequently quantified (predicted pKd) in 
XScore. 
The conformation of abiraterone with the highest 
affinity for the AR_LBP as generated through similarity suite 
analysis was recruited as a template for the de novo design 
exercise. Through this process, molecular fragments were 
modelled in SYBYL which could then be planted and 
allowed growth within the AR_LBP using the GROW 
algorithm in LigBuilder v1.2. 
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Steroid scaffold 
Hydroxyl group 
Seed structure creation was approached judiciously. 
SAR analysis of abiraterone was indicative of the fact that its 
3-pyridyl substituent was responsible for the inhibitory effect 
of abiraterone at the CYP17A1 enzyme.9It was consequently 
decided to retain this moiety, and to then allow freedom of 
growth within the AR_LBP stemming from the terminus of 
the 3-pyridyl group. Molecular modelling was carried out in 
SYBYL and involved the removal of all moieties extraneous 
to the 3-pyridyl group. Furthermore, a change in atom type 
from a sp3 carbon to anH.spc was also carried out in order to 
establish growing sitesfor the GROW module in LigBuilder 
v1.2.This process effectively represented an attempt to 
eliminate the steroidal backbone inherent to abiraterone with 
consequent elimination of the steroidal side effects associated 
with their long-term use.  
 
Results: 
The in silicopredicted pKd for metribolone post 
extraction from its cognate receptor (PDB 1E3G) was 7.44. 
The predicted LBA(pKd) of abiraterone after manual 
superimposition of its steroidal nucleus over that of 
metribolone was estimated to be 7.16. When abiraterone was 
allowed computational freedom within the metribolone 
bound conformation of the AR, 21 high affinity conformers 
were generated with predicted in silico LBA (pKd) that 
ranged between 6.50 and 7.23 (Ref. Table 1). The binding 
energies (kcal mol-1) were also quantified in SYBYL for each 
of the 21 conformations. These ranged from -8.87 to -9.86 
kcal mol-1and are shown, plotted together with predicted in 
silico LBA (pKd) for each of the 21 generated high affinity 
conformations of abiraterone in Figure 5.  
The 3D image of the mapped AR_LBPand a 
proposed pharmacophore based on the bound co-ordinates of 
metribolone are shown in Figure 6. 
Implementation of the de novo design process on 
the prepared seed structure (Ref. Fig. 4)according to the 
GROW algorithm resulted in the elaboration of a total of 83 
molecules which subscribed to 8 families. The best 
conformer from each family was selected as a potential non-
steroidal lead compound based on molecular weight, log P 
and LBA (Ref. Table 2). 
 
 
Figure 4 Abirateroneand the seed structure 
Abiraterone:  
HO
 
 
 
 
Seed Structure: 
H.spc
 
 
 
 
 
3-pyridyl ring 
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Figure 5: Graph of Predicted LBA (pKd)/Binding Energy (kcalmol-1) for the 21 structural conformations of 
Abirateronefor the AR 
Figure 6: LBP mapof metribolone in its cognate crystallographic deposition 1E3G shown in (a) and the respective 
pharmacophoric structure is shown in (b). Hydrogen bond donor grids can be seen in blue, hydrogen bond acceptor 
gridsare shown in red, while hydrophobic gridsare shown in cyan.Images generated using VMD. 
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Table 1: Metribolone, superimposedabirateroneand the 
Structural images generated using Pymol®
 
 
Metribolone 
Abiraterone 
superimposed onto 
the bound 
coordinates of 
metribolone 
Best binding 
conformation of 
Abiraterone 
 
Table 2: The ligands with the highest LBA from each generated family are shown. Structural images were 
 
Molecule No. Family No. 
Chemical 
formula
1 <1> C22H21
48 <2> C25H17
54 <3> C21H19
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best binding conformer of abiraterone for the AR_LBP. 
 
Structure 
Predicted 
LBA 
-log(pKd) 
Predicted binding energy 
 
7.44 
 
7.16 
 
7.23 
generated using Pymol® 
 
 
Molecular 
Weight LogP 
Average 
score 
pKd 
NO 315 5.45 7.23 
N3O 375 5.71 7.10 
NO 301 5.56 6.87 
9) :1-8(2012) 
(kcal/mol) 
-10.15 
-9.77 
-9.86 
3D structure 
 
 
 
7 
BIOMIRROR                               ISSN 0976 
 
75 <4> C22H
77 <5> C23H19
80 <6> C23H24
81 <7> C21H
83 <8> C21H23
 
Discussion: 
The value of this study stems from the fact that the 
abiraterone moiety associated with CYP17A1 inhibition was 
retained in ade novo drug design exercise that aimed to 
identify novel non-steroidal structures bearing a similarity to 
abiraterone, but which also showed high affinity for the AR. 
The implication of this is that these identified novel structures 
would have the potential to simultaneously inhibit CYP17A1, 
hence mimicking the identified mode of action of abiraterone, 
as well as the AR- consequently retaining the traditional
approach to prostate cancer management. The no
nature of these molecules also implies the absence of the 
steroidal adverse effect profile associated with their long term 
use. The evident predictedin silico LBA (pK
for the AR_LBP must be discussed, especially in light of the
proposed mode of action of abiraterone which has CYP17A1 
inhibition and not the AR as its in vitro target. Abiraterone 
had a high in silico predicted binding affinity for the AR, 
which high affinity was recorded irrespective of the approach 
adopted in this study. In fact, when the steroidal nucleus of 
abiraterone was manually superimposed over that of 
metribolone the LBA (pKd) of abiraterone for the AR_LBP, 
the LBA (pKd) was 7.16 (versus 7.44 for metribolone). When 
abiraterone was allowed limited motion (single bond rotation) 
within the AR_LBP the predicted in silico LBA (p
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23N 301 5.96 6.84 
N2O 339 5.10 6.38 
N2O 344 5.88 6.08 
24N2 304 5.63 5.60 
NO 305 5.02 5.26 
 
n-steroidal 
d) of abiraterone 
 
Kd) ranged  
 
 
between 6.50 and 7.23 for the 21 highest affinity 
conformations which again compare well to the LBA 
estimated for metribolone (pKd 7.44). 
These results support the in vitro
Richards7and point towards a possible scenario of dual 
affinity of abiraterone for the AR and the CYP17A1. From an 
in silico perspective it must be pointed out that this study 
adopted a rigid model. The superimposition of abiraterone 
onto metribolone essentially fixed the steroidal backbone of 
abiraterone onto the bioactive conformation of metribolone as 
described in the crystallographic deposition 1E3G. This 
model consequently assumed a rigid ligand and receptor 
binding pocket, in contrast to the second approach in which, 
although the receptor binding pocket was kept rigid, the 
ligand was allowed limited motion within the confines of the 
AR_LBP. Both these approaches consequently require further 
corroboration through dynamic studies, a s
this study already paved the way through the molecular 
simplification processes carried out prior to estimation of 
silicoLBA. More clearly, the elimination of all moieties and 
water molecules considered superfluous to binding was 
important in ensuring that only motion associated with 
binding would be calculated in a process that is both 
computationally and time intensive. 
9) :1-8(2012) 
 
 
 
 
 
 data of Soifer8and 
cenario for which 
in 
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The de novo drug design exercise yielded 83 non-
steroidal ligands subscribing to 8 families with predicted in 
silico LBAs (pKd) ranging from 5.26 to 7.23.Generation of 
these non-steroidal ligands was based on the premise that the 
AR binds with high affinity to a general pharmacophoric 
structure. The generated pharmacophore comprises of 2 polar 
termini; a hydrogen bond donor and a hydrogen bond 
receptor grid, and a hydrophobic core (Ref. Fig. 5). Thus 
through the retention of the 3-pyridyl ring which binds to the 
hydrogen bond donating grid on the AR_LBP, LigBuilder 
v1.2 was able to generate non-steroidal ligands possessing a 
hydrophobic core and a hydrogen bond donor moiety at the 
other hydrogen bond accepting terminus of the AR_LBP.The 
major outcome of this study is the identification of a series of 
novel non-steroidal molecules with demonstrable binding 
affinity for the AR and with the potential for dual activity at 
the CYP17A1 and the AR. These molecules should 
consequently be considered as lead molecules for further 
iterative optimisation and also for inclusion in molecular 
databases that may be used in High Throughput Screening for 
the identification ofantagonists for the AR. 
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